| __timestamp | Arrowhead Pharmaceuticals, Inc. | Johnson & Johnson |
|---|---|---|
| Wednesday, January 1, 2014 | 24419536 | 21954000000 |
| Thursday, January 1, 2015 | 34718089 | 21203000000 |
| Friday, January 1, 2016 | 40998209 | 19945000000 |
| Sunday, January 1, 2017 | 32022880 | 21420000000 |
| Monday, January 1, 2018 | 19110051 | 22540000000 |
| Tuesday, January 1, 2019 | 26556257 | 22178000000 |
| Wednesday, January 1, 2020 | 52275890 | 22084000000 |
| Friday, January 1, 2021 | 80981000 | 20118000000 |
| Saturday, January 1, 2022 | 124431000 | 19046000000 |
| Sunday, January 1, 2023 | 90932000 | 20112000000 |
| Monday, January 1, 2024 | 98761000 | 21969000000 |
Cracking the code
In the ever-evolving landscape of pharmaceuticals, cost management is crucial. Over the past decade, Johnson & Johnson and Arrowhead Pharmaceuticals, Inc. have demonstrated contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Johnson & Johnson consistently maintained SG&A expenses around $20 billion annually, reflecting their expansive global operations. In contrast, Arrowhead Pharmaceuticals, Inc. saw a dramatic increase, with expenses rising over 400% from 2014 to 2023, peaking in 2022. This surge underscores Arrowhead's aggressive growth and investment in innovation. Notably, 2024 data for Johnson & Johnson is missing, highlighting potential reporting delays or strategic shifts. As the pharmaceutical industry continues to grow, understanding these financial dynamics offers valuable insights into corporate strategies and market positioning.
Johnson & Johnson and Merck & Co., Inc.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Johnson & Johnson vs Alnylam Pharmaceuticals, Inc.
Johnson & Johnson and BioMarin Pharmaceutical Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Johnson & Johnson and Exelixis, Inc.
Who Optimizes SG&A Costs Better? Johnson & Johnson or Jazz Pharmaceuticals plc
Comparing SG&A Expenses: Genmab A/S vs Arrowhead Pharmaceuticals, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of Halozyme Therapeutics, Inc. and Arrowhead Pharmaceuticals, Inc.
Comparing SG&A Expenses: Alkermes plc vs Arrowhead Pharmaceuticals, Inc. Trends and Insights
Breaking Down SG&A Expenses: Ultragenyx Pharmaceutical Inc. vs Arrowhead Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Arrowhead Pharmaceuticals, Inc. and Mesoblast Limited
Arrowhead Pharmaceuticals, Inc. vs Celldex Therapeutics, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Arrowhead Pharmaceuticals, Inc. and Evotec SE